Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer

Since gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has been utilized in the management of cancers that progress following first-line therapy.While the pathological response to pembrolizumab is favorable, immune related adverse events (irAEs) can be elicited and re...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Sydney Graham, Emily Sloane, Nadim Bou Zgheib
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Marshall University 2021-04-01
Reeks:	Marshall Journal of Medicine
Onderwerpen:	pembrolizumab immunotherapy immune-related adverse event inflammatory arthritis endometrial cancer arthralgia
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!